Oh, joy. Another article riddled with caveats, as if clarity were ever a priority in the labyrinthine world of medical science. It seems this particular discourse on Drug repositioning needs more than just a fresh coat of paint; it requires a rather significant overhaul to meet the lofty standards of reliable medical references and robust verification . Apparently, relying too heavily on primary sources is akin to trusting a politician’s promises—it rarely ends well. One might suggest adding a few more secondary or tertiary sources to shore up the foundation, lest any primary research articles be challenged and summarily dismissed, like an inconvenient truth at a family gathering. But, I suppose, if you insist on dragging me into this…

Drug Repositioning: Unearthing New Purpose for Old Molecules

Drug repositioning , an endeavor also frequently referred to as drug repurposing , represents a rather pragmatic approach in the relentless pursuit of novel therapeutic interventions. It fundamentally involves the systematic investigation of pharmaceutical compounds—those already approved, extensively studied, and often widely available—for entirely new therapeutic applications, distinct from their original intended use. This isn’t merely a casual afterthought; it’s a deliberate and increasingly sophisticated strategy to bypass some of the most formidable hurdles in traditional drug development. The underlying premise is elegantly simple: why invent the wheel anew when an existing, perfectly functional wheel might just fit a different axle?

Repurposing Achievements

The impact of successfully repositioning generic drugs can be nothing short of transformative for patients, particularly when considering the staggering costs and timelines associated with de novo drug discovery. Indeed, a significant portion—a striking 35%, to be precise—of the ’transformative’ drugs that have garnered approval from the United States Food and Drug Administration (FDA) are, in fact, products of this very repurposing paradigm. This strategy proves especially pertinent and impactful when addressing the often-overlooked realms of rare diseases or those classified as neglected diseases , where the financial incentives for developing entirely new treatments are tragically scarce.

Numerous triumphs underscore the efficacy and potential of this approach. Perhaps the most celebrated instance involves sildenafil , a compound initially developed for cardiovascular issues, which famously found its secondary, far more widely recognized calling as Viagra for the treatment of erectile dysfunction . Less known, but equally critical, is its continued use for pulmonary hypertension , demonstrating its versatile pharmacological profile. Another stark example of serendipity meeting necessity is thalidomide . Once a notorious pharmaceutical pariah due to its teratogenic effects, thalidomide has undergone a remarkable rehabilitation, demonstrating profound efficacy in treating specific manifestations of leprosy and, perhaps even more significantly, in the management of multiple myeloma , albeit under stringent regulatory controls.

Beyond these high-profile cases, the landscape of drug repositioning is dotted with other notable explorations. Clinical trials have, for instance, been meticulously performed on the antifungal agents posaconazole and ravuconazole , investigating their potential as therapeutic candidates for Chagas disease . This pursuit highlights the potential for drugs to cross traditional disease boundaries. Further investigations have extended to other well-established antifungal agents, such as clotrimazole and ketoconazole , which have been thoroughly explored for their potential in anti-trypanosome therapy, targeting parasitic infections that devastate vulnerable populations. This proactive repositioning of antimicrobials has, in fact, been instrumental in the discovery of novel broad-spectrum therapeutics , offering a single agent capable of combating multiple types of infection , a truly invaluable asset in an era of increasing antimicrobial resistance.

Strategy

Drug repositioning is not merely a tactic; it is often hailed as a “universal strategy,” particularly when confronting the daunting challenges posed by neglected diseases . The appeal is multifaceted and profoundly practical, hinging on several key advantages:

1. Reduced Clinical Trial Steps: The most immediate and compelling benefit lies in the significantly reduced number of clinical trial stages typically required for a repurposed drug. Since these compounds have already undergone extensive safety profiling and pharmacokinetic assessments for their initial indication, a considerable portion of the early-stage development (like Phase I clinical trials for toxicity and dosage) can often be streamlined or even bypassed. This drastically cuts down both the time and the exorbitant costs traditionally associated with bringing a new medicine to market, transforming a decade-long odyssey into a potentially shorter journey.
2. Existing Pharmaceutical Supply Chains: The logistical nightmare of manufacturing, formulating, and distributing a novel drug is largely circumvented. Repurposed drugs often benefit from established pharmaceutical supply chains, which can readily facilitate their “formulation and distribution.” This means the infrastructure for getting the drug from the lab to the patient is already largely in place, accelerating accessibility, especially in resource-limited settings.
3. Known Combination Possibilities: The pharmacological profiles of existing drugs are well-characterized, including their interactions with other compounds. This “known possibility of combining with other drugs” allows for the strategic development of more effective, synergistic treatment regimens, a critical advantage in complex diseases that often require multi-drug approaches.
4. Discovery of New Mechanisms: Repurposing isn’t just about finding new uses; it’s also a powerful engine for scientific discovery. It can “facilitate the discovery of new mechanisms of action for old drugs and new classes of medicines.” By observing how an existing drug behaves in a new therapeutic context, researchers can uncover previously unrecognized biological pathways or drug targets, expanding our fundamental understanding of disease and pharmacology.
5. Removal of Early Research Barriers: The initial, often insurmountable “activation barriers” of early research stages—the conceptualization, preliminary screening, and basic target validation—are largely absent. This enables a repurposed project to “advance rapidly into disease-oriented research,” hitting the ground running with a tangible, vetted compound rather than starting from scratch with a theoretical construct.

While often perceived as a somewhat serendipitous approach , where a repurposable drug is stumbled upon by chance—a fortuitous accident, if you will—drug repurposing has, in recent times, profoundly benefited from the relentless march of technological progress. Advances in human genomics , sophisticated network biology analyses, and innovative chemoproteomics techniques have transformed it into a far more systematic and predictive discipline. It is now entirely feasible to identify serious repurposing candidates by meticulously pinpointing genes implicated in a specific disease and subsequently investigating whether these genes interact, within the intricate cellular environment, with other genes that happen to be the known targets of existing, approved drugs. This data-driven approach is not merely academic; it has been empirically demonstrated that drugs targeting mechanisms supported by human genetics are twice as likely to achieve success and ultimately gain approval compared to the general population of drugs languishing in the pharmaceutical pipeline. This underscores the power of aligning drug action with fundamental biological insights.

Furthermore, drug repurposing stands as a potentially time and cost-effective strategy for confronting dreadful diseases, such as the various forms of cancer , where the urgency for new treatments is perpetual. Its adaptability and inherent efficiencies have made it an indispensable tool, notably applied as a means of rapidly finding solutions to combat global health crises, exemplified most recently by its pivotal role during the ongoing COVID-19 pandemic .

Computational Drug Repurposing

The advent of computational power has ushered in a new era for drug repurposing through what is known as computational drug repurposing . This involves the sophisticated in silico screening of already approved drugs to identify potential new indications. This methodology leverages vast datasets, drawing upon molecular, clinical, or biophysical information to predict novel drug-disease associations. More recently, the wealth of information contained within electronic health records (EHRs) and other forms of real-world evidence has gained considerable traction in drug repurposing efforts, proving particularly invaluable during the rapid response necessitated by the COVID-19 pandemic . The primary expectation driving the adoption of computational drug repurposing is its promise to significantly reduce both the prohibitive costs and the protracted timelines traditionally associated with drug development.

A prime example of this in action occurred in 2020, amidst the relentless grip of the COVID-19 pandemic . A prominent European project , known as Exscalate4Cov , embarked on an ambitious computational drug repurposing initiative. Their extensive experiments ultimately led to the identification of raloxifene – a selective estrogen receptor modulator – as a possible candidate for treating patients in the early stages of COVID-19. This demonstrates the tangible, real-world impact of advanced computational methods in crisis situations.

Drug repositioning evidence level (DREL) assessment of repositioning studies

One might imagine that finding a new use for an old drug is a straightforward affair. It is not. To bring some semblance of order and rigor to the chaotic realm of repurposing, the Drug Repositioning Evidence Level (DREL) assessment provides a crucial framework for evaluating the quality of scientific evidence supporting such claims. It’s a sobering reminder that not all “discoveries” are created equal, and the path from a lab bench to a patient’s bedside is paved with increasingly stringent demands for proof.

• Level 0: No evidence; includes in silico predictions without confirmation. This is where the journey often begins, with computational models spitting out probabilities and hypotheses. It’s akin to having a well-informed guess; intriguing, perhaps, but entirely unproven. Without any empirical validation, it remains a mere digital whisper, a theoretical possibility with no tangible footing in reality.
• Level 1: In vitro studies with limited value for predicting in vivo /human situation. Here, the drug is tested in a controlled laboratory environment, often in cell cultures or isolated tissues. While providing initial biological plausibility, these “test tube” experiments are notoriously poor predictors of how a complex biological system, like a human body, will actually respond. It’s a necessary first step, but a very long way from a therapeutic breakthrough.
• Level 2: Animal studies with hypothetical relevance in humans. Progressing to animal models offers a more holistic view, testing the drug within a living organism. However, the leap from mouse to man is often fraught with peril. What works in a rodent might utterly fail, or even prove harmful, in a human. The relevance is often “hypothetical,” a cautious acknowledgment of the physiological differences between species.
• Level 3: Incomplete studies in humans at the appropriate dose e.g. proof of concept; few cases from medical records; some clinical effects observed. This is where the rubber meets the road, albeit tentatively. Early human data, perhaps from compassionate use cases, limited “proof of concept” trials, or retrospective analyses of medical records, offers a glimmer of hope. Clinical effects might be observed, suggesting efficacy, but the data is often sparse, uncontrolled, or lacks the statistical power for definitive conclusions. It’s a promising signal, but far from a clear directive.
• Level 4: Well-documented clinical endpoints observed for repositioned drug at doses within safety limits. The gold standard. At this level, the repurposed drug has demonstrated clear, measurable, and statistically significant clinical benefits in humans, at doses known to be safe. This typically involves well-designed clinical trials with robust methodologies, providing the strong evidence needed for clinical adoption. This is the ultimate goal, the point where a drug truly finds its new, validated purpose.

Challenges

Of course, nothing is ever truly simple, and drug repositioning , despite its allure, is hardly immune to significant hurdles. A systematic review conducted in 2022 meticulously highlighted the principal impediments: a chronic lack of adequate resources, both financial and in terms of crucial subject matter expertise ; formidable barriers to accessing shelved pharmaceutical compounds and their associated, often proprietary, trial data; and, perhaps most critically, the distinct absence of traditional intellectual property (IP) protections for compounds that are merely repurposed rather than newly invented. These factors collectively conspire to make what seems like a logical shortcut a rather treacherous path.

The financial disincentives, in particular, loom large for pharmaceutical companies, especially when considering the repurposing of generic drugs . The crux of the problem is a rather inconvenient truth: once a drug becomes generic, physicians are perfectly at liberty to prescribe it off-label for any indication they deem appropriate, and pharmacists can readily substitute a cheaper generic version for its branded counterpart. This effectively erodes any potential for a developer to recoup the substantial investment required to scientifically validate a new indication. As Pharmacologist Alasdair Breckenridge and patent judge Robin Jacob so succinctly articulated, underscoring the severity of this systemic flaw: “If a generic version of a drug is available, developers have little or no opportunity to recoup their investment in the development of the drug for a new indication.” It’s a glaring economic disincentive that stifles innovation in an area promising immense public health benefits.

Beyond these overarching economic and IP concerns, drug repositioning introduces a host of other practical challenges:

• Dosage Discrepancies: The dosage required to effectively treat a novel disease often diverges significantly from the dosage used for the drug’s original target indication. Should this occur, the discovery team finds itself in the unenviable position of having to initiate comprehensive Phase I clinical trials anew, essentially stripping drug repositioning of its primary advantage over de novo drug discovery—the ability to bypass early-stage testing. This can be a costly and time-consuming setback.
• Formulation and Distribution Complexity: While existing supply chains offer a theoretical advantage, the practicalities of finding new formulation and distribution mechanisms for existing drugs, particularly to novel-disease-affected geographic areas, rarely receive the dedicated attention and expertise of “pharmaceutical and toxicological” scientists. This oversight can lead to suboptimal delivery, stability issues, or even unintended toxicities in a new patient population or environment.
• Patent Right Intricacies: The legal landscape surrounding patent rights for drug repurposing is, to put it mildly, exceptionally complicated. This complexity stems from several factors: a notable scarcity of legal experts specializing in this niche area; the inadvertent disclosure of repositioning potential through online platforms or academic publications, which can preempt patentability; and the intricate question of defining the true “novelty” of a new drug purpose in the eyes of patent law. Navigating these legal minefields often requires as much ingenuity as the scientific discovery itself.

Drug Repurposing in Psychiatry

The realm of psychiatric disorders, with its notoriously complex etiologies and often limited therapeutic options, presents a particularly compelling, if challenging, frontier for drug repurposing . It is widely considered a rapid, cost-effective, and reduced-risk strategy for the development of desperately needed new treatment options within this field. The high failure rate and immense costs associated with developing entirely new psychotropic medications make the repurposing of existing, well-characterized drugs an attractive alternative, offering a glimmer of hope for patients struggling with debilitating mental health conditions.

Bipolar disorder

In the intricate and often devastating landscape of bipolar disorder , repurposed drugs are steadily emerging as feasible and promising augmentation options for existing treatments. A number of agents, each supported by a plausible biological rationale, have undergone rigorous evaluation, seeking to provide additional relief where current monotherapies fall short. Meta-analyses of randomized placebo-controlled trials have provided compelling evidence suggesting that adjunctive allopurinol and tamoxifen demonstrated superiority over placebo specifically for the manic phases of the disorder. Similarly, add-on treatments involving modafinil /armodafinil and pramipexole appeared to show efficacy in addressing the challenging depressive episodes characteristic of bipolar disorder . The efficacy of other agents, such as celecoxib and N-acetylcysteine , however, appeared to be more narrowly confined to specific outcomes, suggesting a more nuanced role in treatment.

Further meta-analytic evidence also exists for the adjunctive use of melatonin and ramelteon in managing mania, and for add-on acetylsalicylic acid , pioglitazone , memantine , and inositol in the treatment of bipolar depression. However, it is crucial to note that the findings for these particular compounds were not deemed statistically significant, indicating a need for more robust and extensive research before definitive conclusions can be drawn.

Despite these promising early signals and the inherent advantages of drug repurposing , the generally low quality of evidence currently available for many of these repurposed drugs means that reliable, evidence-based recommendations for their widespread use in routine clinical practice remain elusive. While some of these agents have undeniably shown encouraging results, they unequivocally demand further, more rigorous investigation in research settings to solidify their therapeutic roles and establish clear guidelines for their application in the complex management of bipolar disorder .

See also

• COVID-19 drug repurposing research
• Chemoproteomics
• Exscalate4Cov
• Lists of investigational drugs